

Anti-depressant drugs

Depression



- **Depression**: ↓ of biological amines in postsynaptic sites (pathological depression).
- **Affection mode disorders**: **Unipolar** [depression without mania] & **Bipolar** (alternating episodes of mania & depression)




Fig. 21.1. Neurotransmitter deficiency syndromes and their interactions.

[i] MAO Inhibitors

- M.O.A:
- Inhibition of *intraneuronal MAO-A enzyme* (which metabolize NE, 5-HT, DA) → ↑ level of amines → anti-depressant effect.
- N.B:
- MAO-B enzyme (metabolize Dopamine only) so, by inhibition → ↓ DA → parkinsonism ttt.
- COMT: Another enzyme metabolizes endogenous amines but present *Extra-neuronal*.

S.E. of MAOIs

Excess tyramine (amino acid) in circulation causes the release of noradrenaline from sympathetic nerves




Increased BP, increased HR,




People taking MAOI's for depression should avoid foods rich in tyramine
(cheese, hot dogs, beans)

MAOI's are contraindicated in people with CV disease, hepatic disease, epilepsy. People taking sympathomimetics,


A. Irreversible non-selective MAOIs

Iproniazide	Phenelzine SO ₄	Tranylcypromine
	 .H ₂ SO ₄	 .H ₂ SO ₄

B) Irreversible	C) Reversible preferential for MAO_A
Deprenyl	Moclobemide
MAO _B inhibitor (anti-parkinsonism)	 <chem>Clc1ccc(cc1)C(=O)NCCCN2CCOCC2</chem>


[II] Tricyclic Antidepressant (Thymoleptics)

- **MOA:** **Block transporters** of NE & 5-HT (due to the structural similarities).
- **Advantage:** *More safe > MAOIs* → No diet control (**may be used for children for nocturnal enuresis**).








Monoamine reuptake transporter.

SAR





3ry Amines	2ry Amine
↓ 5-HT reuptake [$>$ NE] → ↑ 5-HT	↓ NE reuptake → ↑ NE
↑ anti-cholinergic S.E	↓ anti-cholinergic S.E.
With ↑ sedation	Stimulatory


Azepine derivatives		Cylcoheptane derive.
Imipramine (tofranil)	Chlorimipramine (Anafranil)	Amitryptiline (Tryptizole)
 <p><u>Parent Cpd</u></p>		 <p><u>(NO geometrical isomers)</u></p>
<p><u>Metabolism</u> → Desipramine [2ry amine] → <u>more active</u></p>	<ul style="list-style-type: none"> • With <u>higher lipophilicity</u> → <u>more potent</u>. • <u>Cl form H bond with protonated N</u> → <u>stabilize β-aryl amine structure.</u> 	<p><u>Metabolism</u> → Nortriptyline (2ry amine) → active.</p>

Oxepine derivative	Thiepine derivative
Doxipene	Dothiepine (Prothiaden)
	
E Isomer is used	
Bioisosters to Amitryptiline [O or S instead of CH ₂]	


[III] Second generation Anti-depressants

- A. Tetracyclic Anti-depressants

Maprotiline (Ludlomel®)	Mirtazepine (Tolvon®)
	
<p>Selective NE reuptake inhibitors</p>	<p>Related to <u>Mianserine</u> <u>Pyrazino-azepine derivative</u></p>
<ul style="list-style-type: none"> - not stimulant (block other receptors) 	<ul style="list-style-type: none"> • Central α_2-blocker $\rightarrow \uparrow$ NE release.




Dihydrodibenzazepine



Dibenzocycloheptene



Dibenzobicyclooctadiene




Phenothiazine

Three-dimensional models of the tricyclic and tetracyclic ring

D. Selective Serotonin reuptake Inhibitors (SSRI)

- 1st line of treatment - with phenyl ring, basic N (resemble 5-HT) & halogen.
- Bind to SERT [Serotonin Transporter]
- Adverse effects; **Sexual dysfunction** is a common side effect with SSRIs. Specifically, side effects often include difficulty becoming aroused, lack of interest in sex, and anorgasmia (trouble achieving orgasm). Genital anesthesia, loss of or decreased response to sexual stimuli, and ejaculatory anhedonia are also possible. Although usually reversible, these sexual side effects can last for months or years after the drug has been completely withdrawn. This is known as post SSRI sexual dysfunction.

Fluoxetine (Prozac®)



SAR of Fluoxetine:

CF₃ → must be Para. [if m → ↓ selectivity 10 fold] [if O → ↓ selectivity 90 fold].


CF₃ if replaced by ortho-Methoxy (**Nesoxitine**) → NE reuptake inhibitor.

Degree of methylation on N not affect selectivity or potency [**Norfluoxetine is active**].

Fluoxetine → R & S are equal in activity [but S is slowly eliminated].

4- Analeptics (respiratory stimulants)

- M.O.A. : \uparrow *respiratory center in brain.*
- Doxapram




- Taken by **I.V.** infusion in divided doses with 5 min interval.
- * \uparrow selectivity & \downarrow duration \rightarrow \downarrow S.E.s.
- * Uses: ttt of acute or post operative or opioid-induced resp.depression.

Anti-psychotic drugs


[Neuroleptics] [Major tranquilizer]

- Uses: Psychosis, Hallucination, Excitation, anti-emetic [D_2 -blocker at CTZ].
- S.E:
- ① Extra-pyramidal symptoms (EPS) → Parkinsonism like symptoms.
- If typical [\uparrow potency, \uparrow EPS] BUT if Atypical [\downarrow potency, \downarrow EPS]
- ② Anti-cholinergic (\downarrow EPS)
- ③ Anti-histaminic (H_1 -blocker) → sedation.
- ④ Anti-adrenergic (α_1 -blocker) → hypotension.
- ⑤ Photosensitivity. ⑥ Retinal toxicity.

[i] Phenothiazines









- The prototype is Chlorpromazine (CPZ) → obtained from promethazine (antihistaminic).
- CPZ index: relate the anti-psychotic drug activity to that of CPZ (for CPZ = 1)
- Requirements:
 - ① Linear tricycle.
 - ② B = 3 Cs.
 - ③ X gp at C₂ → **e-withdrawing gp** → is **essential** to attract +ve on protonated N of side chain → **superimposition on dopamine receptor**.



Assay of phenothiazines:


3ry amine (weak base) → **non-aqueous titration** [dissolve in glacial acetic acid → titrate against HClO₄ with crystal violet indicator].

Propyl dialkylamino side chain	
CPZ	Triflupromazine
	
Metabolized by <u>N- dealkylation</u> & <u>C₇ Hydroxylation</u>	
<u>S.E</u>: sedation & hypotension Due to α_1 -blockage	<u>Adv</u>: less sedation & less hypotensive than CPZ


Alkyl piperidyl side chain [Atypical → ↓ EPS & ↑ anti-cholinergic]		
Thioridazine	Mesoridazine	Sulphoridazine
	 <p>2 times more active</p>	
<p><u>Metabolism:</u></p> <p>① 1 → 2 → 3 (side chain sulfoxidation)</p> <p>② <u>Ring Sulfoxidation:</u>  both are inactive</p>		

Propyl piperazine side chain [with piperazine → the most potent → ↑ EPS]



Trifluoperazine




Fluphenazine



- Fluphenazine is short acting, So-->
 Esters prodrug used --> latention of ation (depot IM)
 1. Decanoate [-O-CO-(CH₂)₈-CH₃] --> 2-3 weeks
 2. Heptanoate [-O-CO-(CH₂)₅-CH₃] --> 1-2 weeks

[ii] Dibenzodiazepine	[iii] thienobenzodiazepine
Clozapine (leponex)	Olanzapine (Zyprexa)
	
<ul style="list-style-type: none"> • <u>Atypical</u> → ↓ potency due to <u>wrong orientation of N-methyl piperazino gp relative to Cl atom.</u> • ↓ <u>EPS.</u> 	<ul style="list-style-type: none"> • <u>Atypical with ↓ EPS.</u> • <u>More potent</u> antagonist at D₂ & serotonin 5-HT_{2A} receptors > Clozapine.


Quetiapine (Seroquel)



- Atypical antipsychotic, for schizophrenia, bipolar disorders and major depressive disorders.
- Quetiapine is one of the most well tolerated neuroleptics of other atypical antipsychotics by reducing the incidence of extrapyramidal symptoms.
- Quetiapine has the following pharmacological actions:
 - D1, D2, D3 and D4 receptor antagonist.
 - 5-HT1A, 5-HT2A, 5-HT2C and 5-HT7 receptor antagonist.
 - α 1 and α 2-adrenergic receptor antagonist.
 - H1 receptor Antagonist.
 - mACh receptor antagonist.

[iv] Butyrophenone
Haloperidol (Haldol)

Active orally with
lower sedation thn CPZ



R = H Or = decanoete ester --> depot IM/4 weeks


Typical with ↑ potency & ↑ EPS , NO anti-cholinergic

Uses: 1. Drug of choice in terminate **mania**.
2. **Gille de la tourette syndrome** (GDTS) →
abnormal voice, movement.

[v] Benzisoxazole

Risperidone (Risperdal)

-



5-HT_{2A} (main excitatory receptor subtype among the G-protein coupled receptors for 5-HT) & **D₂ antagonist**

- **Atypical.**

- **Not inhibit DA neurotransmission in striatum** & cortex → **low EPS.**

BUT maintain blockage of D₂-limbic receptor.

